Tuesday, Cantor Fitzgerald reaffirmed its Overweight ... The firm's analyst, Olivia Brayer, provided insights into the pharmaceutical company's prospects, particularly focusing on the potential ...
Tuesday, Cantor Fitzgerald reaffirmed its Overweight rating on Vertex ... with analyst targets ranging from $330 to $615. The firm's analyst, Olivia Brayer, provided insights into the pharmaceutical ...
Vertex Pharmaceuticals (VRTX – Research Report) received a Buy rating and a $480.00 price target from Cantor Fitzgerald analyst Olivia Brayer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback